Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy

por Flinn, Ian W., Erter, Jack, Daniel, Davey B., Mace, Joseph R., Berdeja, Jesus G.
Publicado 2019

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

por Donnellan, William, Berdeja, Jesus G., Shipley, Diana, Arrowsmith, Edward R., Wright, David, Lunin, Scott, Brown, Richard, Essell, James H., Flinn, Ian W.
Publicado 2017

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study

por Biran, Noa, Siegel, David, Berdeja, Jesus G., Raje, Noopur, Cornell, Robert Frank, Alsina, Melissa, Kovacsovics, Tibor, Fang, Belle, Kimball, Amy S., Landgren, Ola
Publicado 2019

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion coh...

por Berdeja, Jesus G., Gregory, Tara K., Faber, Edward A., Hart, Lowell L., Mace, Joseph R., Arrowsmith, Edward R., Flinn, Ian W., Matous, Jeffrey V.
Publicado 2021

A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma

por Alsina, Melissa, Landgren, Ola, Raje, Noopur, Niesvizky, Ruben, Bensinger, William I., Berdeja, Jesus G., Kovacsovics, Tibor, Vesole, David H., Fang, Belle, Kimball, Amy S., Siegel, David S.
Publicado 2020

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

por Rowinsky, Eric K., Paner, Agne, Berdeja, Jesus G., Paba-Prada, Claudia, Venugopal, Parameswaran, Porkka, Kimmo, Gullbo, Joachim, Linder, Stig, Loskog, Angelica, Richardson, Paul G., Landgren, Ola
Publicado 2020

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

por Kelly, Kevin R., Shea, Thomas C., Goy, André, Berdeja, Jesus G., Reeder, Craig B., McDonagh, Kevin T., Zhou, Xiaofei, Danaee, Hadi, Liu, Hua, Ecsedy, Jeffrey A., Niu, Huifeng, Benaim, Ely, Padmanabhan Iyer, Swaminathan
Publicado 2013

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

por Kumar, Shaji K., Berdeja, Jesus G., Niesvizky, Ruben, Lonial, Sagar, Laubach, Jacob P., Hamadani, Mehdi, Stewart, A. Keith, Hari, Parameswaran, Roy, Vivek, Vescio, Robert, Kaufman, Jonathan L., Berg, Deborah, Liao, Eileen, Rajkumar, S. Vincent, Richardson, Paul G.
Publicado 2019

Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W...

por Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Publicado 2020

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the...

por Weisel, Katja, Martin, Thomas, Krishnan, Amrita, Jagannath, Sundar, Londhe, Anil, Nair, Sandhya, Diels, Joris, Vogel, Martin, Schecter, Jordan M., Banerjee, Arnob, Berdeja, Jesus G., Nesheiwat, Tonia, Garrett, Ashraf, Qi, Keqin, Valluri, Satish, Usmani, Saad Z., Yong, Kwee
Publicado 2021

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

por Krishnan, Amrita, Kapoor, Prashant, Palmer, Joycelynne M., Tsai, Ni-Chun, Kumar, Shaji, Lonial, Sagar, Htut, Myo, Karanes, Chatchada, Nathwani, Nitya, Rosenzweig, Michael, Sahebi, Firoozeh, Somlo, George, Duarte, Lupe, Sanchez, James F., Auclair, Daniel, Forman, Stephen J., Berdeja., Jesus G.
Publicado 2018

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma

por Richardson, Paul G., Hofmeister, Craig C., Rosenbaum, Cara A., Htut, Myo, Vesole, David H., Berdeja, Jesus G., Liedtke, Michaela, Chari, Ajai, Smith, Stephen D., Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra Di, Estevam, Jose, Berg, Deborah, Baz, Rachid
Publicado 2018

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment...

por Martin, Thomas, Krishnan, Amrita, Yong, Kwee, Weisel, Katja, Mehra, Maneesha, Nair, Sandhya, Qi, Keqin, Londhe, Anil, Diels, Joris, Crivera, Concetta, Jackson, Carolyn C., Olyslager, Yunsi, Vogel, Martin, Schecter, Jordan M., Banerjee, Arnob, Valluri, Satish, Usmani, Saad Z., Berdeja, Jesus G., Jagannath, Sundar
Publicado 2021

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

por Richardson, Paul G., Bensinger, William I., Huff, Carol Ann, Costello, Caitlin L., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Siegel, David S., Lebovic, Daniel, Jagannath, Sundar, Laubach, Jacob P., Stockerl‐Goldstein, Keith E., Kwei, Long, Clow, Fong, Elias, Laurence, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, Vij, Ravi
Publicado 2018

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

por Shah, Nina, Aiello, Jack, Avigan, David E, Berdeja, Jesus G, Borrello, Ivan M, Chari, Ajai, Cohen, Adam D, Ganapathi, Karthik, Gray, Lissa, Green, Damian, Krishnan, Amrita, Lin, Yi, Manasanch, Elisabet, Munshi, Nikhil C, Nooka, Ajay K, Rapoport, Aaron P, Smith, Eric L, Vij, Ravi, Dhodapkar, Madhav
Publicado 2020

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

por Lin, Yi, Raje, Noopur S., Berdeja, Jesús G., Siegel, David S., Jagannath, Sundar, Madduri, Deepu, Liedtke, Michaela, Rosenblatt, Jacalyn, Maus, Marcela V., Massaro, Monica, Petrocca, Fabio, Yeri, Ashish, Finney, Olivia, Caia, Andrea, Yang, Zhihong, Martin, Nathan, Campbell, Timothy B., Rytlewski, Julie, Fuller, Jaymes, Hege, Kristen, Munshi, Nikhil C., Kochenderfer, James N.
Publicado 2023

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD3...

por Mateos, Maria-Victoria, Weisel, Katja, Martin, Thomas, Berdeja, Jesús G., Jakubowiak, Andrzej, Stewart, A. Keith, Jagannath, Sundar, Lin, Yi, Diels, Joris, Ghilotti, Francesca, Thilakarathne, Pushpike, Perualila, Nolen J., Cabrieto, Jedelyn, Haefliger, Benjamin, Erler-Yates, Nichola, Hague, Clare, Jackson, Carolyn C., Schecter, Jordan M., Strulev, Vadim, Nesheiwat, Tonia, Pacaud, Lida, Einsele, Hermann, Moreau, Philippe
Publicado 2022

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

por Stewart, A. Keith, Krishnan, Amrita Y., Singhal, Seema, Boccia, Ralph V., Patel, Manish R., Niesvizky, Ruben, Chanan-Khan, Asher A., Ailawadhi, Sikander, Brumm, Jochen, Mundt, Kirsten E., Hong, Kyu, McBride, Jacqueline, Shon-Nguyen, Quyen, Xiao, Yuanyuan, Ramakrishnan, Vanitha, Polson, Andrew G., Samineni, Divya, Leipold, Douglas, Humke, Eric W., McClellan, James Scott, Berdeja, Jesus G.
Publicado 2019

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

por Martin, Thomas, Usmani, Saad Z., Berdeja, Jesus G., Agha, Mounzer, Cohen, Adam D., Hari, Parameswaran, Avigan, David, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil C., O'Donnell, Elizabeth, Stewart, A. Keith, Schecter, Jordan M., Goldberg, Jenna D., Jackson, Carolyn C., Yeh, Tzu-Min, Banerjee, Arnob, Allred, Alicia, Zudaire, Enrique, Deraedt, William, Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida, Madduri, Deepu, Jakubowiak, Andrzej, Lin, Yi, Jagannath, Sundar
Publicado 2023

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

por Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan T., Jakubowiak, Andrzej, Dingli, David, Cornell, Robert F., Hofmeister, Craig C., Siegel, David, Berdeja, Jesus G., Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol Ann, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay K., Richter, Joshua, Abonour, Rafat, Parker, Terri L., Yee, Andrew J., Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja C., Mohty, Mohamad, Choquet, Sylvain, Unger, T. J., Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Dimopoulos, Meletios Athanasios
Publicado 2020